{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:36:58Z","timestamp":1791423418697,"version":"4.3.3"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T00:00:00Z","timestamp":1562112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"French National Institute for Health and Medical Research"},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"crossref"}]},{"name":"French National Agency"},{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Dual therapy combining integrase inhibitors and NNRTIs represents a promising regimen in ageing HIV-infected individuals with long exposure to nucleoside analogues and PIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The ANRS 163 ETRAL trial (NCT02212379) was a 96\u2009week, multicentre, single-arm study evaluating the efficacy and safety of raltegravir (400\u2009mg twice daily)\/etravirine (200\u2009mg twice daily) in individuals &gt;45\u2009years, on a PI-containing regimen who were integrase inhibitor and etravirine naive. The primary endpoint was the proportion of participants with virological success, defined by the absence of virological failure up to week 48. Main secondary outcomes included evolution of metabolic parameters, CD4\/CD8 count, bone mineral density and inflammatory markers. The study was designed to show an efficacy &gt;90%, assuming a success rate \u226595%, with a power of 80% and a 5% type-1 error.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and sixty-five participants (median age 52\u2009years, duration of ART 16.9\u2009years, viral suppression 6.9\u2009years and CD4 count 700\u2009cells\/mm3) were enrolled. By ITT analysis, viral suppression was maintained in 99.4% of participants (95% CI\u205f=\u205f95.6%\u201399.9%) at week 48 and 98.7% (95% CI\u205f=\u205f95.0%\u201399.7%) at week 96. Two virological failures occurred (week 24 and week 64) without emergence of integrase inhibitor resistance. Eight participants discontinued raltegravir\/etravirine for adverse events, leading to a strategy success rate of 95.1% (95% CI\u205f=\u205f90.5%\u201397.5%) at week 48 and 92.7% (95% CI\u205f=\u205f87.5%\u201395.8%) at week 96. Over 96\u2009weeks, lipid fractions improved (P\u205f&lt;\u205f0.001), CD4\/CD8 ratio increased, IFN\u03b3-induced protein 10 (IP-10) decreased (\u22128.1%), soluble CD14 decreased (\u221227%, P\u205f&lt;\u205f0.001) bone mineral density improved and BMI increased.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Raltegravir plus etravirine dual therapy demonstrated durable efficacy in virologically suppressed ageing patients.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkz224","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T19:11:34Z","timestamp":1561576294000},"page":"2742-2751","source":"Crossref","is-referenced-by-count":35,"title":["Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study"],"prefix":"10.1093","volume":"74","author":[{"given":"Christine","family":"Katlama","sequence":"first","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (APHP), H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service des Maladies Infectieuses et Tropicales, Paris, France"},{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique (IPLESP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Assoumou","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique (IPLESP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Antoine","family":"Valantin","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (APHP), H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service des Maladies Infectieuses et Tropicales, Paris, France"},{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique (IPLESP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathia","family":"Souli\u00e9","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique (IPLESP), Paris, France"},{"name":"APHP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de virologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Clinic and University of Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydie","family":"B\u00e9niguel","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique (IPLESP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouchaud","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris (APHP), Centre Hospitalier Universitaire Avicenne, Service des Maladies Infectieuses et Tropicales, Bobigny, France"},{"name":"Universit\u00e9 Paris 13, IMEA-Fondation Internationale L\u00e9on Mba, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Raffi","sequence":"additional","affiliation":[{"name":"INSERM CIC 1413, Universit\u00e9 de Nantes, D\u00e9partement des Maladies Infectieuses, H\u00f4pital H\u00f4tel-Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Diderot, Paris, France, Sorbonne Paris Cit\u00e9, APHP, H\u00f4pital Saint-Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Fellahi","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM UMRS_938, Institut Hospitalo-Universitaire de Cardio-m\u00e9tabolisme et Nutrition (ICAN), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"INSERM UMR 1137, Universit\u00e9 Paris 7, Laboratoire de Pharmacologie-Toxicologie, H\u00f4pital Bichat-Claude Bernard, APHP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"APHP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Laboratoire de virologie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Kolta","sequence":"additional","affiliation":[{"name":"D\u00e9partement de rhumatologie, H\u00f4pital Cochin, Paris, France - INSERM UMR-1153, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Capeau","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM UMRS_938, Institut Hospitalo-Universitaire de Cardio-m\u00e9tabolisme et Nutrition (ICAN), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Gibowski","sequence":"additional","affiliation":[{"name":"ANRS, France Recherche Nord & Sud Sida-HIV H\u00e9patites, Agence autonome de l\u2019INSERM, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Cardon","sequence":"additional","affiliation":[{"name":"ANRS, France Recherche Nord & Sud Sida-HIV H\u00e9patites, Agence autonome de l\u2019INSERM, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Reynes","sequence":"additional","affiliation":[{"name":"D\u00e9partement de maladies infectieuses, UMI 233 INSERM U1175, CHU de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Costagliola","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique (IPLESP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the members of the ANRS 163 ETRAL study","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bottero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouchaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Chidiac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Duvivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Goujard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"delMarGuti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Morlat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Poizot-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Raffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Reynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Salmon-C\u00e9ron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Antoine","family":"Valantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,3]]},"reference":[{"key":"2019091012301859100_dkz224-B1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(18)31311-4","article-title":"HIV seminar","volume":"392","author":"Ghosn","year":"2018","journal-title":"Lancet"},{"key":"2019091012301859100_dkz224-B2","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2019091012301859100_dkz224-B3","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1473-3099(15)00056-0","article-title":"Future challenges for clinical care of an ageing population infected with HIV: a modelling study","volume":"15","author":"Smit","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2019091012301859100_dkz224-B4","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1016\/S2352-3018(15)00077-6","article-title":"Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study","volume":"2","author":"Rasmussen","year":"2015","journal-title":"Lancet HIV"},{"key":"2019091012301859100_dkz224-B5","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/cid\/ciu701","article-title":"Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study","volume":"59","author":"Schouten","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2019091012301859100_dkz224-B6","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/cid\/cir627","article-title":"Premature age-related comorbidities among HIV-infected persons compared with the general population","volume":"53","author":"Guaraldi","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019091012301859100_dkz224-B7","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2468-2667(16)30020-2","article-title":"Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort","volume":"2","author":"Croxford","year":"2017","journal-title":"Lancet Public Health"},{"key":"2019091012301859100_dkz224-B8","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/QAD.0000000000001476","article-title":"Individualized antiretroviral therapeutic approaches: less can be more","volume":"31","author":"Katlama","year":"2017","journal-title":"AIDS"},{"key":"2019091012301859100_dkz224-B9","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/14656566.2018.1457648","article-title":"Current and emerging two-drug approaches for HIV-1 therapy in ART-na\u00efve and ART-experienced, virologically suppressed patients","volume":"19","author":"Rossetti","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"2019091012301859100_dkz224-B10","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/S0140-6736(14)61170-3","article-title":"Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96-week results from the NEAT001\/ANRS143 randomised non-inferiority trial","volume":"384","author":"Raffi","year":"2014","journal-title":"Lancet"},{"key":"2019091012301859100_dkz224-B11","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1473-3099(14)70736-4","article-title":"Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48-week results of the randomised, open label, non-inferiority GARDEL trial","volume":"14","author":"Cahn","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2019091012301859100_dkz224-B12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1086\/524061","article-title":"Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy","volume":"197","author":"Goicoechea","year":"2008","journal-title":"J Infect Dis"},{"key":"2019091012301859100_dkz224-B13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/QAD.0000000000001666","article-title":"Abacavir use and risk of recurrent myocardial infarction","volume":"32","author":"Sabin","year":"2018","journal-title":"AIDS"},{"key":"2019091012301859100_dkz224-B14","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/S2352-3018(18)30043-2","article-title":"Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study","volume":"5","author":"Ryom","year":"2018","journal-title":"Lancet HIV"},{"key":"2019091012301859100_dkz224-B15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1345\/aph.1P576","article-title":"Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor, and raltegravir-based antiretroviral regimens","volume":"45","author":"Patel","year":"2011","journal-title":"Ann Pharmacother"},{"key":"2019091012301859100_dkz224-B16","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3851\/IMP1662","article-title":"Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials","volume":"15","author":"Katlama","year":"2010","journal-title":"Antivir Ther (Lond)"},{"key":"2019091012301859100_dkz224-B17","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3851\/IMP2344","article-title":"Dual raltegravir\/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy","volume":"17","author":"Calin","year":"2012","journal-title":"Antivir Ther"},{"key":"2019091012301859100_dkz224-B18","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jac\/dkt406","article-title":"Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study","volume":"69","author":"Monteiro","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2019091012301859100_dkz224-B19","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1089\/aid.2016.0291","article-title":"Dual raltegravir-etravirine combination as maintenance regimen in virologically suppressed HIV-1-infected patients","volume":"33","author":"Calza","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2019091012301859100_dkz224-B20","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"2019091012301859100_dkz224-B21","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1128\/AAC.00691-12","article-title":"Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data","volume":"56","author":"Acosta","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2019091012301859100_dkz224-B22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/QAI.0b013e31802b4956","article-title":"Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals","volume":"43","author":"Markowitz","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019091012301859100_dkz224-B23","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1097\/QAD.0000000000001675","article-title":"Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk","volume":"31","author":"Gatell","year":"2017","journal-title":"AIDS"},{"key":"2019091012301859100_dkz224-B24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"Mills","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2019091012301859100_dkz224-B25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2019091012301859100_dkz224-B26","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"2019091012301859100_dkz224-B27","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jac\/dkq544","article-title":"Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia","volume":"66","author":"Wirden","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2019091012301859100_dkz224-B28","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/jac\/dky130","article-title":"Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART","volume":"73","author":"Nouchi","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019091012301859100_dkz224-B29","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/QAD.0b013e32833dec20","article-title":"Efficacy of darunavir\/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136","volume":"24","author":"Katlama","year":"2010","journal-title":"AIDS"},{"key":"2019091012301859100_dkz224-B30","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1097\/QAD.0b013e32833a608a","article-title":"Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study","volume":"24","author":"Mart\u00ednez","year":"2010","journal-title":"AIDS"},{"key":"2019091012301859100_dkz224-B31","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/cid\/ciw017","article-title":"Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s","volume":"62","author":"McComsey","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019091012301859100_dkz224-B32","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/QAD.0000000000001495","article-title":"Dolutegravir and weight gain: an unexpected bothering side effect?","volume":"31","author":"Menard","year":"2017","journal-title":"AIDS"},{"key":"2019091012301859100_dkz224-B33","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiq118","article-title":"Plasma levels of soluble CD14 independently predict mortality in HIV infection","volume":"203","author":"Sandler","year":"2011","journal-title":"J Infect Dis"},{"key":"2019091012301859100_dkz224-B34","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/infdis\/jix082","article-title":"Association of macrophage inflammation biomarkers with progression of subclinical carotid artery atherosclerosis in HIV-infected women and men","volume":"215","author":"Hanna","year":"2017","journal-title":"J Infect Dis"},{"key":"2019091012301859100_dkz224-B35","doi-asserted-by":"crossref","first-page":"e0161594.","DOI":"10.1371\/journal.pone.0161594","article-title":"Low CD4\/CD8 ratio is associated with non AIDS-defining cancers in patients on antiretroviral therapy: ANRS CO8 (Aproco\/Copilote) prospective cohort study","volume":"11","author":"Hema","year":"2016","journal-title":"PLoS One"},{"key":"2019091012301859100_dkz224-B36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/QAI.0000000000001723","article-title":"Raltegravir 1200 mg once daily vs 400 mg twice daily, with emtricitabine and tenofovir disoproxil fumarate, for previously untreated HIV-1 infection: week 96 results from ONCEMRK, a randomized, double-blind, noninferiority trial","volume":"78","author":"Cahn","year":"2018","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkz224\/28901545\/dkz224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/9\/2742\/29205914\/dkz224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:55:58Z","timestamp":1663808158000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/9\/2742\/5528001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,3]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,7,3]]},"published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz224","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2019,7,3]]}}}